109 related articles for article (PubMed ID: 32599977)
1. EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation.
Park S; Ku BM; Jung HA; Sun JM; Ahn JS; Lee SH; Park K; Ahn MJ
Cancer Res Treat; 2020 Oct; 52(4):1288-1290. PubMed ID: 32599977
[TBL] [Abstract][Full Text] [Related]
2. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.
Cho BC; Felip E; Hayashi H; Thomas M; Lu S; Besse B; Sun T; Martinez M; Sethi SN; Shreeve SM; Spira AI
Future Oncol; 2022 Feb; 18(6):639-647. PubMed ID: 34911336
[TBL] [Abstract][Full Text] [Related]
3. Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201.
Chul Cho B; Han JY; Hyeong Lee K; Lee YG; Kim DW; Joo Min Y; Kim SW; Kyung Cho E; Kim JH; Lee GW; Sook Lee S; Lee N; Young Wang J; Park H; Ahn MJ
Lung Cancer; 2024 Apr; 190():107509. PubMed ID: 38432025
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
Chabon JJ; Simmons AD; Lovejoy AF; Esfahani MS; Newman AM; Haringsma HJ; Kurtz DM; Stehr H; Scherer F; Karlovich CA; Harding TC; Durkin KA; Otterson GA; Purcell WT; Camidge DR; Goldman JW; Sequist LV; Piotrowska Z; Wakelee HA; Neal JW; Alizadeh AA; Diehn M
Nat Commun; 2016 Jun; 7():11815. PubMed ID: 27283993
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and evaluation of new pyrimidine derivatives as EGFR
Mao YZ; Xi XX; Zhao HY; Zhang YL; Zhang SQ
Bioorg Med Chem Lett; 2023 Jul; 91():129381. PubMed ID: 37336419
[TBL] [Abstract][Full Text] [Related]
6. Real-world clinical evidence of lazertinib use in acquired
Park S; Jung HA; Lee SH; Ahn JS; Ahn MJ; Sun JM
Transl Lung Cancer Res; 2023 Sep; 12(9):1912-1922. PubMed ID: 37854157
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, activity, and their relationships of 2,4-diaminonicotinamide derivatives as EGFR inhibitors targeting C797S mutation.
Kageji H; Momose T; Nagamoto Y; Togashi N; Yasumatsu I; Nishikawa Y; Kihara K; Hiramoto K; Minami M; Kasanuki N; Isoyama T; Naito H
Bioorg Med Chem Lett; 2024 Jan; 98():129575. PubMed ID: 38065292
[TBL] [Abstract][Full Text] [Related]
8. Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448).
Heppner DE; Wittlinger F; Beyett TS; Shaurova T; Urul DA; Buckley B; Pham CD; Schaeffner IK; Yang B; Ogboo BC; May EW; Schaefer EM; Eck MJ; Laufer SA; Hershberger PA
ACS Med Chem Lett; 2022 Dec; 13(12):1856-1863. PubMed ID: 36518696
[TBL] [Abstract][Full Text] [Related]
9. The Efficacy of Pemigatinib in Advanced NSCLC With FGFR Aberration: Case Report.
Gao M; Wang L; Jing F; Zhang F; Tao H; Hu Y
Clin Lung Cancer; 2024 Jan; 25(1):e62-e66. PubMed ID: 37940412
[No Abstract] [Full Text] [Related]
10. Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis.
Vijayaraghavan S; Lipfert L; Chevalier K; Bushey BS; Henley B; Lenhart R; Sendecki J; Beqiri M; Millar HJ; Packman K; Lorenzi MV; Laquerre S; Moores SL
Mol Cancer Ther; 2020 Oct; 19(10):2044-2056. PubMed ID: 32747419
[TBL] [Abstract][Full Text] [Related]
11. EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins.
Remon J; Hendriks LEL; Cardona AF; Besse B
Cancer Treat Rev; 2020 Nov; 90():102105. PubMed ID: 32979839
[TBL] [Abstract][Full Text] [Related]
12. Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC.
Nagasaka M; Zhu VW; Lim SM; Greco M; Wu F; Ou SI
J Thorac Oncol; 2021 May; 16(5):740-763. PubMed ID: 33338652
[TBL] [Abstract][Full Text] [Related]
13. CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation.
Kashima K; Kawauchi H; Tanimura H; Tachibana Y; Chiba T; Torizawa T; Sakamoto H
Mol Cancer Ther; 2020 Nov; 19(11):2288-2297. PubMed ID: 32943545
[TBL] [Abstract][Full Text] [Related]
14. Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status.
Lee J; Choi Y; Han J; Park S; Jung HA; Su JM; Lee SH; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2020 Nov; 15(11):1758-1766. PubMed ID: 32652216
[TBL] [Abstract][Full Text] [Related]
15. Osimertinib in Resected
Wu YL; Tsuboi M; He J; John T; Grohe C; Majem M; Goldman JW; Laktionov K; Kim SW; Kato T; Vu HV; Lu S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Zeng L; Hodge R; Atasoy A; Rukazenkov Y; Herbst RS;
N Engl J Med; 2020 Oct; 383(18):1711-1723. PubMed ID: 32955177
[TBL] [Abstract][Full Text] [Related]
16. Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib.
Sun Y; Meyers BA; Czako B; Leonard P; Mseeh F; Harris AL; Wu Q; Johnson S; Parker CA; Cross JB; Di Francesco ME; Bivona BJ; Bristow CA; Burke JP; Carrillo CC; Carroll CL; Chang Q; Feng N; Gao G; Gera S; Giuliani V; Huang JK; Jiang Y; Kang Z; Kovacs JJ; Liu CY; Lopez AM; Ma X; Mandal PK; McAfoos T; Miller MA; Mullinax RA; Peoples M; Ramamoorthy V; Seth S; Spencer ND; Suzuki E; Williams CC; Yu SS; Zuniga AM; Draetta GF; Marszalek JR; Heffernan TP; Kohl NE; Jones P
Cancer Res; 2020 Nov; 80(21):4840-4853. PubMed ID: 32928921
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore.
Aziz MIA; Foo WYX; Toh CK; Lim WT; Ng K
J Med Econ; 2020 Nov; 23(11):1330-1339. PubMed ID: 32886557
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Selpercatinib in
Drilon A; Oxnard GR; Tan DSW; Loong HHF; Johnson M; Gainor J; McCoach CE; Gautschi O; Besse B; Cho BC; Peled N; Weiss J; Kim YJ; Ohe Y; Nishio M; Park K; Patel J; Seto T; Sakamoto T; Rosen E; Shah MH; Barlesi F; Cassier PA; Bazhenova L; De Braud F; Garralda E; Velcheti V; Satouchi M; Ohashi K; Pennell NA; Reckamp KL; Dy GK; Wolf J; Solomon B; Falchook G; Ebata K; Nguyen M; Nair B; Zhu EY; Yang L; Huang X; Olek E; Rothenberg SM; Goto K; Subbiah V
N Engl J Med; 2020 Aug; 383(9):813-824. PubMed ID: 32846060
[TBL] [Abstract][Full Text] [Related]
19. Histological transformation of lung adenocarcinoma to small cell lung cancer with mutant C797S conferring acquired resistance to osimertinib.
Ren X; Cai X; Li J; Zhang X; Yu J; Song X; Zhang H; Song X
J Int Med Res; 2020 Jun; 48(6):300060520927918. PubMed ID: 32600081
[TBL] [Abstract][Full Text] [Related]
20. Lazertinib: First Approval.
Dhillon S
Drugs; 2021 Jun; 81(9):1107-1113. PubMed ID: 34028784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
